ArticleFrontiers in pharmacology2026
Prediction of early treatment response to drug-eluting beads chemoembolization for hepatocellular carcinoma using machine learning.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug-eluting bead trans-arterial chemoembolization (DEB-TACE) has been extensively employed as a locoregional therapy for hepatocellular carcinoma (HCC). In this work, machine-learning algorithms are used to forecast early treatment response in HCC patients undergoing DEB-TACE. Methods: We collected data on patients with HCC who underwent anthracycline-loaded DEB-TACE at our institution over two periods: July 2023 to November 2024 and January to September 2025. The treatment response was evaluated at 1, 3, and 6 months after therapy by dynamic contrast-enhanced computed tomography (CT) based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Univariable and multivariable logistic regression analyses were conducted. Independent predictors identified were used to build the predictive model. Machine learning models were evaluated using multiple performance metrics, including AUC, accuracy, sensitivity, and specificity, across the internal validation set and the temporal validation cohort. Results: A total of 299 HCC patients were included (196 internal cohort, 103 temporal validation cohort), with objective response rates at 1, 3, and 6 months of 56.1%, 51.2%, and 45.9% for the internal cohort and 57.3%, 52.4%, and 49.5% for the temporal validation cohort. Risk factor analysis identified independent predictors of treatment response at various time points, including age, BCLC stage, tumor distribution, and largest tumor diameter. LR showed the highest AUC across all time points, with values of 0.830, 0.840, and 0.854 in the internal validation set and 0.817, 0.832, and 0.839 in the temporal validation cohort at M1, M3, and M6. Subgroup analyses suggested generally consistent predictive performance of the LR model across selected treatment-related subgroups. Conclusion: In the treatment of hepatocellular carcinoma with DEB-TACE, machine learning models demonstrated promising performance in predicting early treatment response, supporting the development of personalized treatment strategies in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.